vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and CSW INDUSTRIALS, INC. (CSW). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $233.0M, roughly 1.1× CSW INDUSTRIALS, INC.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 4.4%, a 6.7% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 20.3%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $22.7M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 5.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
ANIP vs CSW — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $233.0M |
| Net Profit | $27.5M | $10.3M |
| Gross Margin | — | 39.7% |
| Operating Margin | 14.1% | 7.4% |
| Net Margin | 11.1% | 4.4% |
| Revenue YoY | 29.6% | 20.3% |
| Net Profit YoY | 367.5% | -61.9% |
| EPS (diluted) | $1.14 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $233.0M | ||
| Q3 25 | $227.8M | $277.0M | ||
| Q2 25 | $211.4M | $263.6M | ||
| Q1 25 | $197.1M | $230.5M | ||
| Q4 24 | $190.6M | $193.6M | ||
| Q3 24 | $148.3M | $227.9M | ||
| Q2 24 | $138.0M | $226.2M | ||
| Q1 24 | $137.4M | $210.9M |
| Q4 25 | $27.5M | $10.3M | ||
| Q3 25 | $26.6M | $40.7M | ||
| Q2 25 | $8.5M | $40.9M | ||
| Q1 25 | $15.7M | $35.1M | ||
| Q4 24 | $-10.3M | $26.9M | ||
| Q3 24 | $-24.2M | $36.1M | ||
| Q2 24 | $-2.3M | $38.6M | ||
| Q1 24 | $18.2M | $31.8M |
| Q4 25 | — | 39.7% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 43.8% | ||
| Q1 25 | — | 44.2% | ||
| Q4 24 | — | 41.4% | ||
| Q3 24 | — | 45.6% | ||
| Q2 24 | — | 47.5% | ||
| Q1 24 | — | 44.4% |
| Q4 25 | 14.1% | 7.4% | ||
| Q3 25 | 15.9% | 20.5% | ||
| Q2 25 | 6.6% | 20.8% | ||
| Q1 25 | 13.3% | 19.5% | ||
| Q4 24 | -2.3% | 15.3% | ||
| Q3 24 | -13.8% | 22.6% | ||
| Q2 24 | 3.7% | 24.3% | ||
| Q1 24 | 14.8% | 21.0% |
| Q4 25 | 11.1% | 4.4% | ||
| Q3 25 | 11.7% | 14.7% | ||
| Q2 25 | 4.0% | 15.5% | ||
| Q1 25 | 8.0% | 15.2% | ||
| Q4 24 | -5.4% | 13.9% | ||
| Q3 24 | -16.3% | 15.8% | ||
| Q2 24 | -1.7% | 17.1% | ||
| Q1 24 | 13.2% | 15.1% |
| Q4 25 | $1.14 | $0.62 | ||
| Q3 25 | $1.13 | $2.41 | ||
| Q2 25 | $0.36 | $2.43 | ||
| Q1 25 | $0.69 | $2.05 | ||
| Q4 24 | $-0.45 | $1.60 | ||
| Q3 24 | $-1.27 | $2.26 | ||
| Q2 24 | $-0.14 | $2.47 | ||
| Q1 24 | $0.82 | $2.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $40.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $1.1B |
| Total Assets | $1.4B | $2.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $40.2M | ||
| Q3 25 | $262.6M | $31.5M | ||
| Q2 25 | $217.8M | $38.0M | ||
| Q1 25 | $149.8M | $225.8M | ||
| Q4 24 | $144.9M | $213.8M | ||
| Q3 24 | $145.0M | $273.2M | ||
| Q2 24 | $240.1M | $18.9M | ||
| Q1 24 | $228.6M | $22.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $800.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $166.0M |
| Q4 25 | $540.7M | $1.1B | ||
| Q3 25 | $505.8M | $1.1B | ||
| Q2 25 | $436.8M | $1.1B | ||
| Q1 25 | $418.6M | $1.1B | ||
| Q4 24 | $403.7M | $1.0B | ||
| Q3 24 | $405.9M | $1.0B | ||
| Q2 24 | $455.8M | $650.2M | ||
| Q1 24 | $452.0M | $615.7M |
| Q4 25 | $1.4B | $2.3B | ||
| Q3 25 | $1.4B | $1.5B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.4B | ||
| Q4 24 | $1.3B | $1.4B | ||
| Q3 24 | $1.3B | $1.4B | ||
| Q2 24 | $920.8M | $1.1B | ||
| Q1 24 | $914.5M | $1.0B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $28.9M |
| Free Cash FlowOCF − Capex | $29.1M | $22.7M |
| FCF MarginFCF / Revenue | 11.8% | 9.8% |
| Capex IntensityCapex / Revenue | 0.5% | 2.6% |
| Cash ConversionOCF / Net Profit | 1.10× | 2.81× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $162.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $28.9M | ||
| Q3 25 | $44.1M | $61.8M | ||
| Q2 25 | $75.8M | $60.6M | ||
| Q1 25 | $35.0M | $27.3M | ||
| Q4 24 | $15.9M | $11.6M | ||
| Q3 24 | $12.5M | $66.8M | ||
| Q2 24 | $17.4M | $62.7M | ||
| Q1 24 | $18.3M | $22.4M |
| Q4 25 | $29.1M | $22.7M | ||
| Q3 25 | $38.0M | $58.7M | ||
| Q2 25 | $71.8M | $57.7M | ||
| Q1 25 | $32.5M | $22.8M | ||
| Q4 24 | $13.5M | $8.5M | ||
| Q3 24 | $7.7M | $61.3M | ||
| Q2 24 | $13.0M | $59.6M | ||
| Q1 24 | $13.7M | $17.5M |
| Q4 25 | 11.8% | 9.8% | ||
| Q3 25 | 16.7% | 21.2% | ||
| Q2 25 | 34.0% | 21.9% | ||
| Q1 25 | 16.5% | 9.9% | ||
| Q4 24 | 7.1% | 4.4% | ||
| Q3 24 | 5.2% | 26.9% | ||
| Q2 24 | 9.4% | 26.3% | ||
| Q1 24 | 10.0% | 8.3% |
| Q4 25 | 0.5% | 2.6% | ||
| Q3 25 | 2.7% | 1.1% | ||
| Q2 25 | 1.9% | 1.1% | ||
| Q1 25 | 1.3% | 2.0% | ||
| Q4 24 | 1.3% | 1.6% | ||
| Q3 24 | 3.2% | 2.4% | ||
| Q2 24 | 3.2% | 1.4% | ||
| Q1 24 | 3.3% | 2.3% |
| Q4 25 | 1.10× | 2.81× | ||
| Q3 25 | 1.66× | 1.52× | ||
| Q2 25 | 8.87× | 1.48× | ||
| Q1 25 | 2.23× | 0.78× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 1.85× | ||
| Q2 24 | — | 1.62× | ||
| Q1 24 | 1.00× | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
